Candida auris (C. auris) belongs to the Candida genus and is a fungal yeast resistant to multiple drugs. It is highly virulent and evades current therapeutic remedies. It was first discovered in a Japanese hospital in 2009 from a patient's external auditory canal [1] . C. auris infection has a high worldwide mortality, which ranges from 30% to 60%, and is frequently associated with bloodstream infections [2] .The rapid spread of C. auris infection occurred after 2009. The Centers for Disease Control and Prevention (CDC) has estimated the presence of C. auris isolates in 41 countries, typically in hospital settings, as of March 2020 [3] . CDC also reported outbreaks of infections with C. auris in 47 countries globally on February 15, 2021 [4] . The United States reported 2377 clinical cases and 5754 screening cases from January 2022 to December 2022 [5] . Twenty-six isolates of C. auris from India were different genetically and phenotypically from the ones found in Japan and Korea, which provided evidence for C. auris's ability to mutate and its resistance to Azoles [6] .The mechanism of C. auris virulence factors is relatively unknown. According to genomic comparison, C. auris has the ability to adapt to different environments. Two mechanisms of its pathogenesis have been identified, which include hydrolytic enzyme production and attack host cells and tissues. It can also form biofilms that protect it from antifungal drugs and increase its ability in nosocomial transmission [4] .C. auris can be spread in health care facilities such as hospitals and nursing homes through direct patient-to-patient contact. Contaminated surfaces are a significant culprit in the spread when a person comes in contact with them. As C. auris colonizes the skin and can be transmitted into the environment, both properties make it easily transmissible. Population susceptible are immunocompromised people, recently hospitalized patients in areas where C. auris is endemic; catheter use, extended stay in ICU, previous history of antimicrobial exposure, and resistance to antifungal therapy [7] .
Antibiotic resistance has become a critical public health issue due to the overuse and misuse of antibiotics. Despite ongoing efforts to develop stronger antibiotics, bacterial resistance continues to evolve, leading to a global crisis. Effective antibiotics are becoming scarce, and diseases that were once treatable are now becoming uncontrollable. There is a need for new solutions to preserve the current antibiotic arsenal and combat bacterial resistance. Narrow-spectrum antibiotics which do not contribute to multidrug resistance could be a solution instead of broad-spectrum antibiotics. One potential solution is phage therapy, which uses bacteriophages to target specific bacteria without harming healthy cells. Plants are another potential solution because they contain natural antibacterial compounds like polyphenols and alkaloids. Antimicrobial proteins (AMPs) from eukaryotes can also be a good substitute for antibiotics because they do not require a receptor and minimize the chance of bacterial resistance. A clinical trial on women with recurrent UTI was performed. The results of which revealed that overall methenamine hippurate is effective in reducing the intake of antibiotics. Whole genome sequencing is a rapidly evolving method through which resistance pathways are identified to tackle resistance. Developing metallophores is an area of great potential and metal complexes are more likely to advance towards becoming a clinically approved replacement to antibiotics. The development of new solutions is critical to prevent the spread of antibiotic-resistant bacteria and ensure that bacterial infections remain treatable.
Background Hypertension, a leading cause of global mortality and morbidity, affects approximately 1.28 billion adults worldwide, with most cases occurring in low- and middle-income countries. Despite several methods for managing mild to moderate hypertension, effective management of severe or resistant hypertension remains challenging. Renal denervation, a promising non-pharmacological technique, has emerged as a potential solution. Main body Renal denervation works by modifying the renal sympathetic nerve supply through techniques such as ultrasound, radiofrequency energy, or injection of neurolytic agents, reducing blood pressure. Clinical trials, including the RADIANCE series, have shown consistent effectiveness of ultrasound renal denervation in lowering blood pressure, especially in patients who were previously unresponsive to anti-hypertensive medications. After a follow-up of 2 months, mean ambulatory systolic blood pressure during the daytime decreased significantly in the ultrasound renal denervation group compared to the sham group. However, further research is needed to determine renal denervation's long-term safety and efficacy. Conclusions In conclusion, renal denervation holds great potential in improving the treatment of uncontrolled or resistant hypertension treatment, but more investigations and trials are necessary to establish its effectiveness and safety.
Budd-Chiari syndrome is a rare medical condition that affects one in a million people and can be caused by various thrombotic and non-thrombotic factors. In rare instances, multiple factors may contribute to its development, with coagulation factor deficiencies being a less commonly implicated cause. This case report presents a case of BCS associated with protein C deficiency and antiphospholipid syndrome (APLS). The patient is a 30-year-old woman who was brought in due to sudden abdominal distension. She had a three weeks history of intractable vomiting and loose stools. There was also a history of repeated miscarriages. The laboratory findings revealed slightly elevated liver enzymes, a positive Anti-β2 GPI screening, moderately decreased Protein C level and activated protein C resistance/FV Leiden. The patient was discharged after 21 days of inpatient treatment with symptomatic improvement.
Nonalcoholic fatty liver disease (NAFLD), which results in fat accumulation in the cells of the liver, is the most common chronic liver disease in the West [1] . Type 2 diabetes, insulin resistance, and central obesity are all metabolic conditions directly connected to NAFLD [1] . The term "NAFLD" describes several liver conditions that can afflict the population that consumes little or no alcohol [2] . The gravest form of NAFLD, nonalcoholic steatohepatitis (NASH), is defined by extensive scarring (cirrhosis) and liver failure. NASH can lead to liver disease in its latter stages and raises the risk of cardiovascular disease. [3,4] NASH is anticipated to become a substantial public health concern in the upcoming years. The number of NASH cases in the United States alone is predicted to reach 27 million by 2030 [5,6] . In Europe, there were 1.8 million instances of NASH in 2016; this number is predicted to rise by 49% by 2030. In contrast, there were 3.33 million cases of NASH in Germany in 2016; this number is expected to increase by 43% by 2030 [5] . The occurrence of NASH cases is anticipated to grow by 20%-35% in the Asia regions under study between 2019 and 2030 [7] . China is predicted to have the most NASH cases by 2030, followed by the United States and Japan [8] .Weight loss is frequently advised for persons with NASH or NAFLD. However, no approved pharmaceutical or medical remedies for these conditions yet exist. The US Food and Drug Administration and the European Medicines Agency have not yet approved any medications that can be used to treat NAFLD or NASH. [9,10] To attain meaningful clinical remission rates in NASH, weight loss of at least 10% is required [9] . However, it is uncommon to achieve significant weight loss through lifestyle changes alone [11] . Recent antiobesity drugs, including semaglutide or tirzepatide, have shown 12%-17% weight loss effects [12,13] . According to a
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.